Table 3 Reasons for interruption of darunavir/cobicistat
| Dual therapy | Triple therapy | Total | ||||
|---|---|---|---|---|---|---|
| N = 72 | % | N = 177 | % | N = 249 | % | |
| Adverse events | 1 | 1.4 | 12 | 6.8 | 13 | 5.2 |
| Simplification/proactive switch | 1 | 1.4 | 14 | 7.9 | 15 | 6.0 |
| Patient’s preference/low adherence | 2 | 2.8 | 6 | 3.4 | 8 | 3.2 |
| Therapeutic failure | 2 | 2.8 | 0 | 0.0 | 2 | 0.8 |
| Death | 0 | 0.0 | 2 | 1.1 | 2 | 0.8 |
| Drug-drug interaction | 1 | 1.4 | 3 | 1.7 | 4 | 1.6 |
| Other reasons | 1 | 1.4 | 1 | 0.6 | 2 | 0.8 |
| Lost to follow-up | 8 | 11.1 | 18 | 10.2 | 26 | 10.4 |